Logo of Botanix Pharmaceuticals (ASX:BOT)Latest Botanix Pharmaceuticals (ASX:BOT) News

Page 3
Page 3 of 3

Botanix’s Sofdra™ Hits AUD 25M with Strong Prescriber Momentum

Botanix Pharmaceuticals reports robust early sales and expanding prescriber engagement for Sofdra™, its FDA-approved topical gel for excessive underarm sweating, signaling promising growth ahead.
Ada Torres
8 July 2025

Botanix Secures US$30M Debt Facility to Accelerate Sofdra™ Growth

Botanix Pharmaceuticals has secured a US$30 million debt facility from Kreos Capital, bolstering its financial position to commercialize Sofdra™ and pursue platform expansion opportunities.
Ada Torres
10 June 2025

Botanix Addresses Price Volatility Amid US Drug Pricing Rumors

Botanix Pharmaceuticals has clarified that recent share price movements are linked to a rumored US executive order on drug pricing, confirming no undisclosed material information. The company reassures investors of compliance with ASX disclosure rules amid market speculation.
Ada Torres
12 May 2025

Botanix Dismisses US Drug Pricing Impact Amid Trump Executive Order Proposal

Botanix Pharmaceuticals clarifies its lead product Sofdra is unlikely to face price cuts under the proposed US executive order on drug pricing, citing its exclusive US market approval and distinct formulations abroad.
Ada Torres
12 May 2025

Botanix Pharmaceuticals Launches Sofdra, Eyes Revenue Surge in 2025

Botanix Pharmaceuticals has initiated the commercial rollout of Sofdra, its FDA-approved treatment for primary axillary hyperhidrosis, with first prescriptions dispensed and a fully trained sales force deployed. The company anticipates meaningful revenue growth starting in the first quarter of 2025, backed by strong payer contracts and a robust cash position.
Victor Sage
31 Jan 2025